These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new ...

Liraglutide, a GLP-1 significantly lowers the rate of recurrent stroke in patients with diabetes, with no apparent increase ...

A recent study found that over a third of websites selling compounded diabetes and weight loss medications, such as Ozempic and Wegovy, falsely claim they are FDA-approved.

Key Takeaways New data show that GLP1-RA meds like semaglutide can help slow the progression of chronic kidney diseaseThe ...

The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy.

A latest research led by Dr Shuyao Zhang, an assistant professor of internal medicine at UT Southwestern in Dallas reveal the ...

The beverage giant is ready to manage, mitigate and adjust to the “dynamic macro environment,” including potential tariffs ...

GLP-1 RA initiation was not significantly associated with an increased overall risk for thyroid cancer versus the other diabetes drugs in the modified intention-to-treat analysis (hazard ratio [HR ...

Study finds that a significant proportion of adults prescribed GLP-1 RAs for weight management discontinue treatment within a ...

UK: A recent consensus statement from leading UK medical organizations-including the Association of Anaesthetists,the ...